

KOS Diagnostic Lab (A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mr. GAURAV PAUL

AGE/ GENDER : 45 YRS/MALE **PATIENT ID** : 1575382

COLLECTED BY : 012408090005 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 09/Aug/2024 07:45 AM BARCODE NO. :01514753 **COLLECTION DATE** : 09/Aug/2024 07:45AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 09/Aug/2024 09:33AM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Value Unit **Biological Reference interval** Test Name

CLINICAL CHEMISTRY/BIOCHEMISTRY

LIPID PROFILE: BASIC

CHOLESTEROL TOTAL: SERUM mg/dL **OPTIMAL:** < 200.0 237.52^H by CHOLESTEROL OXIDASE PAP

BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0

OPTIMAL: < 150.0

TRIGLYCERIDES: SERUM 206.93H mg/dL by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)

BORDERLINE HIGH: 150.0 - 199.0

HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0

HDL CHOLESTEROL (DIRECT): SERUM 65.13 LOW HDL: < 30.0 mg/dL

by SELECTIVE INHIBITION

BORDERLINE HIGH HDL: 30.0 -

60.0 $HIGH\ HDL: > OR = 60.0$

LDL CHOLESTEROL: SERUM **OPTIMAL:** < 100.0

131^H mg/dL by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 100.0 - 129.0

BORDERLINE HIGH: 130.0 - 159.0

HIGH: 160.0 - 189.0 **VERY HIGH: > OR = 190.0**

NON HDL CHOLESTEROL: SERUM 172.39^H **OPTIMAL: < 130.0** mg/dL

by CALCULATED, SPECTROPHOTOMETRY ABOVE OPTIMAL: 130.0 - 159.0 **BORDERLINE HIGH: 160.0 - 189.0**

> HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0

VLDL CHOLESTEROL: SERUM 41.39 mg/dL 0.00 - 45.00

TOTAL LIPIDS: SERUM 681.97 mg/dL 350.00 - 700.00

by CALCULATED, SPECTROPHOTOMETRY CHOLESTEROL/HDL RATIO: SERUM **RATIO** LOW RISK: 3.30 - 4.40 3.65

AVERAGE RISK: 4.50 - 7.0

MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0

2.01 **RATIO** LOW RISK: 0.50 - 3.0



LDL/HDL RATIO: SERUM

by CALCULATED, SPECTROPHOTOMETRY

by CALCULATED, SPECTROPHOTOMETRY

CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





KOS Diagnostic Lab

(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra

MD (Pathology)

CEO & Consultant Pathologist

NAME : Mr. GAURAV PAUL

AGE/ GENDER : 45 YRS/MALE PATIENT ID : 1575382

COLLECTED BY : REG. NO./LAB NO. : 012408090005

 REFERRED BY
 : 09/Aug/2024 07:45 AM

 BARCODE NO.
 : 01514753
 COLLECTION DATE
 : 09/Aug/2024 07:45 AM

 CLIENT CODE.
 : KOS DIAGNOSTIC LAB
 REPORTING DATE
 : 09/Aug/2024 09:33 AM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name	Value	Unit	Biological Reference interval	
by CALCULATED, SPECTROPHOTOMETRY			MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0	
TRIGLYCERIDES/HDL RATIO: SERUM	3.18	RATIO	3.00 - 5.00	

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

*** End Of Report ***



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana